Bio-Connect

b-Myb antibody, N-term

GTX77893
GeneTex
ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetMYBL2
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    b-Myb antibody, N-term
  • Delivery Days Customer
    9
  • Application Supplier Note
    WB: 0.2-2.5 ug/ml. IHC-P: 2-10 ug/ml. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    ImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    0.5-1 mg/ml
  • Conjugate
    Unconjugated
  • Gene ID4605
  • Target name
    MYBL2
  • Target description
    MYB proto-oncogene like 2
  • Target synonyms
    B-MYB, BMYB, myb-related protein B, myb-like protein 2, v-myb avian myeloblastosis viral oncogene homolog-like 2, v-myb myeloblastosis viral oncogene homolog-like 2
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDP10244
  • Protein Name
    Myb-related protein B
  • Scientific Description
    The protein encoded by this gene, a member of the MYB family of transcription factor genes, is a nuclear protein involved in cell cycle progression. The encoded protein is phosphorylated by cyclin A/cyclin-dependent kinase 2 during the S-phase of the cell cycle and possesses both activator and repressor activities. It has been shown to activate the cell division cycle 2, cyclin D1, and insulin-like growth factor-binding protein 5 genes. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2013]
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203

References

  • Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors. Patel AJ et al., 2019 Oct 22, Proc Natl Acad Sci U S A
    Read more
  • Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Parisi F et al., 2010, Breast Cancer Res
    Read more